MDxHealth SA (MDXH)
| Previous close | 3.1400 |
| Open | 3.1500 |
| Bid | 2.2700 x 200 |
| Ask | 3.9600 x 200 |
| Day's range | 3.0700 - 3.1500 |
| 52-week range | 0.3500 - 4.6400 |
| Volume | |
| Avg. volume | 70,905 |
| Market cap | 83.774M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.6600 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.80 |
Insider MonkeyMDxHealth SA (NASDAQ:MDXH) Q1 2024 Earnings Call Transcript
MDxHealth SA (NASDAQ:MDXH) Q1 2024 Earnings Call Transcript May 4, 2024 MDxHealth SA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the MDxHealth First Quarter 2024 Earnings Call. At this time, all […]
GlobeNewswireMDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed Year-over-year Q1 revenues increase by 35% to $19.8 millionIncreasing 2024 revenue guidance to $83-85 million, previously $79-81 million Conference call with Q&A today at 08:30 AM ET / 14:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 1, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the first qu
- GlobeNewswire
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostic company, announces the introduction of a non-invasive genetic prostate cancer test through its urology sales channel. With a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient’s risk
